We found previously that mice injected intracerebrally ( i.c. ) with a mixture of malignant cells and allogeneic fibroblasts genetically engineered to secrete interleukin -2 ( IL -2 ) survived longer than mice in various control groups. The primary goal of this study was to determine if an established i.c. glioma ( Gl261 ) or breast carcinoma ( SB -5b ) could be treated by injection of IL -2 -secreting allogeneic fibroblasts into the tumor region. As an additional objective, these results were compared with the effectiveness of injecting IL -2 -secreting allogeneic fibroblasts prior to the introduction of the tumor cells as a means of preventing the development of an i.c. glioma or breast carcinoma. The results demonstrated that treatment of mice bearing an established i.c. glioma or breast carcinoma with IL -2 -secreting allogeneic fibroblasts resulted in a prolonged survival. Furthermore, the results demonstrate a significant delay ( P < .005 ) in the development of glioma in the animals treated with either allogeneic nonsecreting or IL -2 -secreting fibroblasts prior to introduction of tumor cells. In addition, 50% of the animals pretreated with IL -2 -secreting allogeneic fibroblasts injected subsequently with Gl261 glioma cells did not develop a tumor, whereas all of the animals injected with glioma cells alone and 92% of those treated with nonsecreting fibroblasts eventually died. Evidence also exists that long -term immunity was established in the treated animals because there was a significant prolongation of survival in comparison to naïve controls ( P < .01 ) for those animals without evidence of glioma that previously had been immunized with treatment cells when challenged again with tumor cells. In a parallel experiment, 62% of the animals pretreated with nonsecreting allogeneic fibroblasts and 75% of the animals pretreated with allogeneic IL -2 -secreting fibroblasts subsequently injected with SB -5b breast carcinoma cells did not develop tumors. The results indicate that IL -2 -secreting allogeneic fibroblasts can be effective in the treatment of an established brain tumor. These data also suggest that i.c. injection of allogeneic IL -2 -secreting fibroblasts is effective in prevention of the development of a brain tumor when the fibroblasts are introduced into the same site where the tumor is subsequently injected.
A n emerging strategy in the treatment of cancer involves stimulation of an immunologic response against the neoplastic cells. The hope is that the immune system can be called into play to destroy the malignant cells. However, in most instances, proliferating tumors do not provoke antitumor cellular immune responses. The precise mechanisms that enable antigenic neoplasms to escape host immunity are incompletely understood. The cells appear to escape recognition by the immune system in spite of the fact that neoplastic cells form weakly immunogenic tumorassociated antigens (TAAs ). Successful methods to induce immunity to TAAs could lead to tumor cell destruction and prolong the survival of cancer patients. A variety of approaches have been used to increase the antigenic properties of tumor cells. In some instances, objective evidence of tumor regression has been observed in patients receiving immunizations only with tumor cell immunogens, suggesting the potential effectiveness of this type of immunotherapy for malignant neoplasms. 1 Recent advances in our understanding of the biology of the immune system have led to the identification of numerous cytokines that modulate immune responses. 2 -4 These agents mediate many of the immune responses involved in antitumor immunity. Interleukin -2 (IL -2) is an important cytokine in the generation of antitumor immunity. 5 In response to tumor antigens, the helper T-cell subset of lymphocytes secretes small quantities of IL -2. This IL -2 acts locally at the site of tumor antigen presentation to activate cytotoxic T cells and natural killer cells that mediate tumor cell destruction. Intravenous, intralymphatic, or intralesional administration of IL -2 has resulted in clinically significant responses in several types of cancer. 5 -9 However, severe toxicities ( hypotension and edema ) limit the dose and efficacy of intravenous and intralymphatic IL -2 administration. 6, 8 The toxicity of systemically administered cytokines is not surprising because these agents mediate local cellular interactions, and they are normally secreted in quantities too small to have systemic effects. To circumvent the toxicity of systemic IL -2 administration, intralesional injection of IL -2 has been attempted. 9, 10 This approach eliminates the toxicity associated with systemic IL -2 administration. However, multiple intralesional injections are required to optimize therapeutic efficacy.
9,10 These injections will be impractical for many patients, particularly when tumor sites are not accessible for direct injection without potential significant morbidity.
The use of allogeneic rather than syngeneic cells for introduction of antitumor immunity was based initially upon evidence that allogeneic MHC determinants augmented the immunogenic properties of tumor vaccines. 11 -13 Like other allografts, the allogeneic cytokine -secreting cells are rejected. Furthermore, the number of vaccine cells can be expanded as desired for multiple rounds of therapy. The slow, continuous release of cytokines and the eventual rejection of the allograft may be a useful advantage in the treatment of a variety of tumors, where long -term secretion of high concentrations of cytokines may be associated with increased morbidity. These considerations provide the rationale for investigating the use of allogeneic fibroblasts genetically modified to secrete cytokines as a means of enhancing antitumor immune responses.
Several groups, including our own, have demonstrated the efficacy of active tumor immunotherapy with cytokinetransduced syngeneic or allogeneic fibroblasts. 11 -16 Our initial studies in a murine intracerebral (i.c. ) glioma or breast carcinoma tumor model involved i.c. injections of IL -2-transduced fibroblasts mixed with tumor cells, which generated systemic antitumor immunity capable of eradicating i.c. tumors. 16, 17 This form of treatment is particularly attractive for primary gliomas because these tumors usually only recur locally and are rarely metastatic. Our previous studies involved mixing the IL-2 -secreting cells with the tumor cells before injecting the mixture into the brains of mice. The goal of this study was to determine if an established brain tumor could be treated by injection of the allogeneic fibroblasts through a microcannula system. These microcannula studies more closely simulate the human clinical situation encountered in patients with brain tumors. An additional goal was to determine if IL -2 -secreting allogeneic fibroblasts are effective in preventing the development of an i.c. glioma or breast carcinoma. In these experiments, the vaccine was injected through a microcannula system prior to the introduction of tumor cells. Preparation of IL -2 -secreting mouse fibroblasts IL -2-secreting LM mouse fibroblasts (LM -IL -2 cells) were prepared as described previously. 12 In brief, the IL -2 gene was transduced into LM fibroblasts with the retroviral vector pZipNeoSVIL -2 (obtained originally from T. Taniguchi, Institute for Molecular and Cellular Biology, Osaka University, Osaka, Japan ). 18 The vector contained the human IL -2 gene and the neo r gene, both under control of the Moloney mouse leukemia virus long terminal repeat. Human IL -2 has been found to be effective in this mouse model. 12 The neo r gene confers resistance to neomycin ( G418 ), an aminoglycoside antibiotic. 19 Helper-free stocks of recombinant retroviruses generated from the GP + env AM12 packaging cell line were used to transduce the LM cells. 20 Every third passage, the cells were placed in growth medium containing 300 g /mL G418. Under these circumstances, IL -2 secretion was maintained. Like unmodified cells, LM fibroblasts transduced with pZipNeoSVIL-2 divided approximately every 24 hours. b and 1 g of pBabePuro were mixed with Lipofectin ( Gibco BRL, Grand Island, NY ), according to the supplier's instructions. The plasmid pBabePuro ( obtained from MKL Collins, University College, London, England, UK ), conferring resistance to puromycin, was used for selection. The plasmid mixture was added to 1Â10 6 LM or LM -IL-2 cells in 10 mL of DMEM, without FBS. For use as a control, an equivalent number of LM or LM -IL-2 cells were transfected with 1 g of pBabePuro alone. The cells were incubated for 18 hours at 378C in a CO 2 /air atmosphere, washed with DMEM, followed by the addition of growth medium. After incubation for 48 hours, the cell cultures were divided and replated in growth medium supplemented with 3.0 g/mL puromycin (Sigma ) followed by incubation at 378C for seven additional days. The surviving colonies were pooled
Materials and methods

Cell lines and experimental animals
Modification of LM or LM -IL -2 fibroblasts ( H -
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Assay for IL -2 secretion
IL -2 secretion by the transfected cells was measured by use of an enzyme-linked immunosorbent assay (ELISA ) kit ( Endogen, Woburn, MA ), according to the manufacturer's instructions.
Intracerebral injection of mice
A cannula system, which we developed and previously described, 21 was modified for injection of tumor cells and the modified fibroblasts. Small screws (0 -80Â1 /16; 1.6 mm in length) were obtained from Plastics One (Roanoke, VA ) and a 0.022 -diameter hole was subsequently drilled through the center of the screw. Mice were anesthesized and a small burr hole was placed with a D#60 drill bit ( Plastics One ) over the right frontal lobe in the region of the coronal suture. The screws bearing a central hole were subsequently secured into the small burr hole using Elmer's Super Glue Gel. The mice were allowed to recover and, on specified days, injections were made using a Hamilton syringe containing a 26 -gauge needle with a small piece of solder placed 5 mm from the tip of the needle to maintain a uniform depth of injection. The total injection volume was 5-10 L.
Statistical analysis
Student's t test was used to determine the statistical differences between the survival of mice in various experimental and control groups. A P value below .05 was considered significant.
Results
Survival of C3H / He mice with i.c. breast carcinoma treated with IL -2 -secreting syngeneic / allogeneic fibroblasts Dose -response studies. Initially, the survival of mice injected i.c. with varying numbers of breast cancer cells was determined. Varying numbers of tumor cells were injected i.c. and the period of survival was measured. The results (Fig 1 ) indicated that the mean survival time (MST ) was inversely related to the number of tumor cells injected. Based on these results, 10
4 SB -5b cells were used in all subsequent experiments. It should be noted that this tumor is grown by in vivo passage, and there are some necrotic cells in the tumor mixture, which varies somewhat between each experiment. Some variability in the mean survival of untreated animals exists between each experimental study upon i.c. injection of this tumor.
Simultaneous injection of tumor and treatment cells. On the basis of previous experiments, 10 6 cytokine-secreting cells were chosen as the treatment dose. 16, 17 Confirmation of IL -2 secretion by the LM -IL -2/ K b cells was detected by an ELISA (Table 1 ) 
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Immuno-gene therapy for brain tumors T Lichtor et al ( P <.05 ) ( Fig 2) . Thus, the presence of IL -2 -secreting fibroblasts in the tumor bed prolonged survival in mice with i.c. breast carcinoma. were mixed with the treatment cells and introduced through the cannulas 1 week following the second injection. The results demonstrate that prior treatment with syngeneic / allogeneic fibroblasts prevented the development of a breast carcinoma in 62% of the animals injected with nonsecreting fibroblasts and 75% of the animals treated with syngeneic / allogeneic IL-2 -secreting fibroblasts (Fig 3 ) . This experiment was repeated one additional time with similar results.
Treatment of an established i.c. breast carcinoma. To determine if the cytokine -secreting cells could be effective in treating a clinically relevant model of mice with an established i.c. breast cancer, naïve C3H / He mice were implanted with cannulas. The animals were subsequently injected initially with tumor cells followed 2 days later by the first of three weekly injections of treatment cells ( LM-K b or LM -IL -2 /K b ). The results indicated a small but significant prolongation of survival (P < .05) for the mice bearing an i.c. breast carcinoma treated through the cannula system implanted into the tumor bed with IL -2-secreting syngeneic /allogeneic fibroblasts ( Fig 4 ) .
Survival of mice with i.c. glioma treated with IL -2 -secreting syngeneic / allogeneic fibroblasts
Protection studies. We found previously that the survival of C57Bl /6 mice injected with Gl261 glioma cells mixed with allogeneic IL -2 -secreting fibroblasts is significantly prolonged in comparison to various control groups. 16 In previous studies, we also found that allogeneic LM -IL -2 fibroblasts modified to express H -2K b determinants (syngeneic in C57Bl /6 mice) to form semiallogeneic LM-IL -2 / K b cells are more effective than IL -2-secreting fibroblasts that express allogeneic determinants alone in treating mice with Gl261 glioma. 22 In order to investigate the mechanism 
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Immuno-gene therapy for brain tumors T Lichtor et al involved in using these genetically engineered cells for treatment of an i.c. tumor, cannulas were placed into the right frontal lobe of C57Bl /6 mice. The animals were subsequently injected two times at weekly intervals with LM -IL-2/K b cells through the cannulas prior to injection of glioma cells. The tumor cells were mixed with the vaccine and introduced through the cannulas 1 week following the second injection. The results demonstrate a significant delay in the development of glioma ( P <.005 ) in the animals treated with either nonsecreting cells or IL -2 -secreting syngeneic /allogeneic fibroblasts ( Fig 5 ) .
Evidence of long -term immunity. Six animals in the IL -2-treated group that survived for over 3 months were then rechallenged with an i.c. injection into the same site as the previous injections of 5Â10 4 Gl261 glioma cells alone to determine if a long -term resistance toward glioma had been established in these animals. The results demonstrated a significant prolongation of survival (P < .01) for those animals that had been previously injected with a mixture of tumor and LM -IL -2/K b cells in comparison to the naïve animals injected with glioma cells alone ( Fig 6 ) . There were four long -term survivors ( >90 days ) of the six total animals in the group previously treated with LM -IL2/K b cells after receiving a second tumor challenge. These results suggest that a long -term immunity was established at the injection site in the animals that underwent multiple i.c. injections of LM -IL -2/ K b cells prior to tumor injection. Whether or not a more generalized systemic immunity against glioma was established in these animals has not been determined.
Treatment of an established i.c. glioma. To determine if the cytokine-secreting cells could be effective in treating a clinically relevant model of mice with an established glioma, naïve C57Bl /6 mice bearing cannulas were first injected with Gl261 glioma followed 2 days later with injection of either non -IL -2-secreting allogeneic LM fibroblasts or syngeneic / allogeneic LM -IL -2 /K b cells. The animals received two more injections of the same type of cells as first injected through the cannulas at weekly intervals for a total of three injections. The animals with an established glioma treated with IL -2 -secreting syngeneic / allogeneic fibroblasts survived significantly longer in comparison to either untreated animals ( P <.05 ) or animals treated with allogeneic LM fibroblasts ( P < .025 ) (Fig 7 ) . This experiment was repeated one additional time with similar results.
Discussion
These data suggest that the i.c. injection of IL -2 -secreting syngeneic /allogeneic fibroblasts into the tumor bed is sufficient to inhibit the development of either a primary or metastatic brain tumor. Furthermore, non -IL -2-secreting syngeneic /allogeneic fibroblasts were also found to be effective in preventing the development of an i.c. tumor, confirming the potential benefit of allogeneic cells alone in stimulating an antitumor response. Also, allogeneic fibroblasts that secrete IL -2 can be used to treat an established primary or metastatic brain tumor, although the results are much less dramatic compared to studies when the vaccine is injected prior to introduction of tumor cells or when the vaccine is mixed with the tumor cells. Allogeneic nonsecreting fibroblasts are not effective in treating an established tumor or when introduced at the same time as the tumor cells. It would appear, therefore, that this treatment strategy is most effective when the tumor burden is minimal, 
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Immuno-gene therapy for brain tumors T Lichtor et al but it is much more difficult to achieve significant prolongation of survival when the cytokine -secreting allogeneic fibroblasts are injected into an actively growing tumor of any significant size. Nevertheless, the induction of antitumor immunity demonstrated in this study is consistent with our previous results that have documented the development of strong antitumor immune responses following the i.c. administration of IL -2 -secreting allogeneic fibroblasts into the tumor bed of animals with brain tumors. 16, 17 It is conceivable that other cytokines, including IL -4, GM -CSF, INF -, or IL -12 either in combination with IL-2 or alone, may improve the results. Also, it is possible that synergistic effects involving this treatment strategy for i.c. tumors may occur upon the addition of chemotherapeutic agents and radiation therapy.
The use of fibroblasts for cytokine administration is an attractive method of therapy because many of the side effects of high -dose systemic administration have not been observed. The i.c. injection of the cytokine -secreting cells alone has not led to significant long -term side effects. 16, 21 Allogeneic rather than syngeneic cells were chosen for local cytokine administration for several reasons. It has been shown that foreign MHC determinants can augment the immunogenic properties of a tumor vaccine. 12, 23 Genetic modification of a cell line rather than cells from a primary neoplasm has other important advantages for use in tumor treatment. Modification of neoplastic cells taken directly from tumor-bearing patients may be difficult. A primary tumor cell line required for retroviral modification has to be established. The establishment of a cell line from a primary neoplasm is not always possible. It is also conceivable that a subpopulation of the primary tumor, selected for its capacity to grow in vitro, may not reflect the tumor cell population as a whole especially because tumors such as breast cancer or gliomas in particular are known to be heterogeneous in their immunogenic properties. The use of tumor cells as the vehicle of cytokine delivery is of concern because the cells themselves may grow into a tumor. Like other allografts, the allogeneic cytokine-secreting cells are rejected. Furthermore, the cells can be expanded as desired for multiple rounds of therapy. In addition, the slow, continuous release of cytokines and the eventual rejection of the allograft may be a useful advantage in the treatment of brain tumors where long -term secretion of high concentrations of certain cytokines may be associated with increased morbidity.
We found previously that allogeneic cells survive in the CNS for only approximately 2 weeks. 21 Thus, the advantages of using an allogeneic cell line are that it is reliable, readily available, stably transfected, not tumorigenic, and more immunogenic. The data presented here raise the possibility that injection of IL -2-secreting fibroblasts directly into an i.c. primary or metastatic tumor may be a useful approach in treatment especially when the tumor burden is small.
